Reach Us +1 218 451 2974
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Pathogenesis of Ebola Viral Haemorrhagic Fever: TTP-like Syndrome Associated with Hepatic Coagulopathy based on "Two Activation Theory of the Endothelium"

Jae Chang*

Department of Medicine, University of California Irvine School of Medicine, Irvine, California, USA

*Corresponding Author:
Jae Chang
Department of Medicine
University of California Irvine School of Medicine
Irvine, California, USA
Tel: 949-387-2207
Email: [email protected]

Received date: May 13, 2017; Accepted date: June 02, 2017; Published date: June 08, 2017

Citation: Chang J. Pathogenesis of Ebola Viral Haemorrhagic Fever: TTP-like Syndrome Associated with Hepatic Coagulopathy based on "Two Activation Theory of the Endothelium". J Prev Inf Cntrl. 2017, 3:1.

Copyright: © 2017 Chang J. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Prevention and Infection Control


Ebola viral haemorrhagic fever is rare but the lifethreatening haemorrhagic disorder associated with Ebola viral sepsis. The demise of the patient occurs due to severe inflammation, multi-organ dysfunction syndrome and haemorrhage associated with a poorly defined coagulopathy. Ebola virus causes endothelial injury that orchestrates inflammation and multi-organ dysfunction, especially in the liver. To address clinical and hematological features, a novel pathogenesis based on “two-activation theory of the endothelium” is proposed. Endothelial injury activates endothelial cells that promote various clinical syndromes such as consumptive thrombocytopenia, multiorgan dysfunction and thrombotic microangiopathy. Endotheliopathy initiates two independent molecular events at endothelial cells: 1) Release of inflammatory cytokines, and 2) Activation of the platelet and exocytosis of unusually large von Willebrand factor multimers. The former triggers activation of inflammatory pathway and the latter mediates activation of microthrombotic pathway. In Ebola viral sepsis, activation of inflammatory pathway causes inflammation, but activation of microthrombotic pathway manifests as disseminated intravascular microthrombosis (DIT). The pathogenesis of Ebola viral haemorrhagic fever is hepatic coagulopathy triggered by acute hepatic necrosis as a result of endotheliopathyassociated DIT, which could manifest as TTP-like syndrome.


Viral haemorrhagic fevers; Disseminated intravascular coagulation (DIC) Endotheliopathy; Thrombocytopenia; Multi-organ dysfunction syndrome (MODS); Thrombotic thrombocytopenic purpura (TTP) TTPlike syndrome


Ebola viral haemorrhagic fever is a rare but life-threatening haemorrhagic disorder occurring in Ebola viral sepsis. Ebola viruses are found in several African countries. Ebola was first discovered in 1976 near the Ebola River in what is now the Democratic Republic of the Congo. Since then, outbreaks have appeared sporadically in Africa according to the Centers for Disease Control and Prevention (CDC) [1].

Clinical features of Ebola viral haemorrhagic fever include inflammatory symptoms such as fever, myalgia, arthralgia, malaise and weakness. Haemorrhagic signs are petechiae, bleeding in internal organs and from bodily orifices like the mouth, eyes, or ears. Some patients develop bloody diarrhea. Eventually, critically ill patients could progress to more serious conditions, including seizures, delirium, shock, and multi-organ dysfunction.

Thrombocytopenia in critically ill patients (TCIP)

Potential causes of Ebola haemorrhagic disease include: 1) thrombocytopenia related to bone marrow suppression from viral sepsis [2], 2) disseminated intravascular coagulation (DIC) [3,4], and 3) hepatic coagulopathy associated with virus-induced hepatitis/hepatic necrosis [5,6]. However, no credible clinical and laboratory data have been documented to explain the underlying coagulopathy.

Although Ebola haemorrhagic fever occurs with thrombocytopenia [7,8], its relationship to bleeding is not clearly determined because thrombocytopenia is typically mild to moderately severe and it alone can’t be accountable for the severe haemorrhagic disorder. Thus, thrombocytopenia has not entered as a serious issue in caring of Ebola infection other than platelet transfusion to maintain it at a safe level.

Just like other sepsis from bacteria, viruses, fungi or parasites, Ebola sepsis is often associated with TCIP [9]. This term has been applied to etiology-undetermined thrombocytopenia after exclusion of known causes of acute thrombocytopenia (e.g., heparin-induced, drug or transfusion-associated, DIC-associated, hypersplenism-related). An interesting finding is that TCIP not only occurs in sepsis/septic shock, but also occurs in other critical illnesses (e.g. severe trauma, complications of surgery, pregnancy and transplant, and immunologic and collagen vascular diseases).

Recently, significant correlation was noted between the degree of thrombocytopenia and severity of the critical illness as well as prognosis and the likelihood of recovery [10,11]. Severer thrombocytopenia has been associated with systemic inflammatory response syndrome (SIRS) and multi-organ dysfunction syndrome (MODS) [12,13]. These observations support TCIP is an important participant in the pathogenesis of the critical illness.

Endotheliopathy and “two-activation theory of the endothelium”

Viral haemorrhagic fevers, including Ebola, are known to cause the injury of endothelial cells (ECs) leading to endotheliopathy and endothelial dysfunction [14-18]. It is known that endotheliopathy triggers molecular events that promote the activation of two independent endothelial pathways (i.e., inflammatory and microthrombotic). Based on these molecular events, a hypothesis of “two-activation theory of the endothelium” is proposed (Figure 1) [5]. In short, two important molecular events are: 1) release of inflammatory cytokines (e.g., interleukin (IL)-1, IL-6, tumor necrosis factor-α, and others) [19,20], and 2) activation of the platelet and exocytosis of unusually large von Willebrand factor multimers (ULVWF) [21-23]. The former triggers inflammation through “activation of inflammatory pathway” and the latter mediates microthrombogenesis via “activation of microthrombotic pathway” as illustrated in Figure 1. In endotheliopathy, microthrombogenesis is the process in which long elongated ULVWF strings that are anchored to ECs recruit activated platelets to decorate and assemble platelet-ULVWF complexes as microthrombi [23-25]. This mechanism results in disseminated intravascular microthrombosis (DIT) triggering thrombotic thrombocytopenis purpura (TTP)-like syndrome.


Figure 1: Pathogenesis of DIT/TTP-like syndrome in Ebola viral haemorrhagic fever.

Endotheliopathy-associated DIT is TTP-like syndrome

DIT is the underlying pathological condition leading to vascular microthrombootic disease (VMTD). Systemic VMTD includes two clinical disorders: thrombotic thrombocytopenic purpura (TTP) and TTP-like syndrome. In TTP, microthrombogenesis begins in circulation due to hyperactivity of ULVWF in both hereditary and antibody-associated type. On the other hand, in TTP-like syndrome developing in viral haemorrhagic fevers, it occurs at the intravascular surface of injured ECs. The pathogenesis and clinical characteristics of TTP and TTP-like syndrome are summarized in Table 1. DIT made of microthrombic that are consisting of platelet-ULVWF complexes and anchored to ECs can be called endotheliopathy-associated DIT/VMTD.

  Antibody-associated TTP Endotheliopathy-associated TTP-like syndrome
Etiology Anti-ADAMTS13 antibody ECs injury leading to dysfunction due to sepsis, surgery, trauma, Shiga toxin, preeclampsia, cancer, drugs, and others
Probable pathogenesis Increased destruction of ADAMTS13 Release of ULVWF and anchored to ECs
  Hyperactive ULVWF® Aggregate with platelet Decorated ULVWF with platelets
  Microthrombosis Microthrombosis
ADAMTS13 level Usually <5% Usually 20-70%
ADAMTS13 antibody Positive Negative
Intravascular ULVWF Increased Increased
Thrombocytopenia Present Present
Schistocytes Always present at usually >2% May be present with fewer schistocytes
Hypoxic organ dysfunction Present Present
Typical example of examples of involving organs Brain (CNSD); Kidneys (ARF) Brain (CNSD); lungs (ARDS); liver (HELLP); kidneys (HUS); bowels (GIHS); liver (AHNS); adrenals (Waterhouse-Friderichsen syndrome) muscle (rhabdomyolysis); skin (purpura fulminans)
Advanced stage of organ involvement MODS SIRS; MODS
Coagulopathy Absent Absent unless hepatic coagulopathy occurs
Response to TPE Very good response Excellent response if treated early
Platelet transfusion Contraindicated Contraindicated

Table 1: Acquired vascular microthrombotic disease (DIT/VMTD): Pathogenic and clinical characteristics of TTP and TTP-like syndrome; DIT: Disseminated Intravascular Thrombosis; VMTD: Vascular Microtrombotic Disease; TTP: Thrombotic Thrombocytopenic Purpura; SIRS: Systemic Inflammatory Response Syndrome; CNSD: Central Nervous System Dysfunction; ARDS: Acute Respiratory Distress Syndrome; GIHS: Gastrointestinal Hemorrhagic Syndrome; AHNS: Acute Fulminant Hepatitis/Acute Hepatic Necrosis Syndrome; ARF: Acute Renal Failure; HUS: Hemolytic Uremic Syndrome; HELLP: Hemolysis, Elevated Liver Enzyme, Low Platelet Syndrome; TPE: Therapeutic Plasma Exchange; ULVWF: Unusually Large von Willebrand Factor Multimers; MODS: Multi-Organ Dysfunction Syndrome; MAHA: Microangiopathic Hemolytic Anemia; aMAHA: Atypical Microangiopathic Hemolytic Anemia; ECs: Endothelial Cells.

In viral haemorrhagic fevers, endotheliopathy-associated DIT/ VMTD could trigger TTP-like syndrome [5,26-29], which is characterized by consumptive thrombocytopenia, microangiopathic hemolytic anemia (MAHA)/atypical MAHA (aMAHA) (if schistocytes are fewer in number) and hypoxic organ dysfunction syndromes. Unlike DIC, in which an abnormal hemostatic (coagulation) disorder occurs following tissue factor (TF) pathway activation, endotheliopathy-associated DIT/VMTD is a pathological microthrombotic disorder occurring as a result of microthrombogenesis. The TF pathway is not involved and coagulation factors are not depleted in the endotheliopathyassociated DIT/VMTD.

Is Ebola viral haemorrhagic fever “DIC”?

The simple answer is no. All the viral haemorrhagic fevers have been attributed to “DIC” [3,4,7]. In clinical medicine, “DIC” mainly has been diagnosed on clinical pretense and confirmed based on a scoring system of the International Society on Thrombosis and Haemostasis (ISTH). Because of misconception of “DIC”, DIT in the critically ill patient has been interpreted as the marker for a hemostatic (coagulation) disorder. This diagnosis hasn’t been based on more reliable coagulation factor assay of FVIII and FV, which are typically depleted in true DIC as seen in acute promyelocytic leukemia [30].

Donald McKay in early1950s coined the term “DIC” [31] for a coagulation disorder that is caused by abnormally activated intravascular thrombotic state. He and his followers believed intravascular microthrombi in the luminal arterioles and capillaries in the pathologic tissue examination were made of micro-clots of platelets, coagulation factors and fibrin. In coagulation profile, the supporting evidence was prolonged prothrombin and activated partial thromboplastin time, hypofibrinogenemia, and increased fibrin degradation products. In many patients with “DIC”, the coagulation profile was perfectly normal and haemorrhagic tendency did not occur. Puzzled but conveniently, the concept of “chronic/compensated/ covert” was introduced. This description, however, cannot explain inexplicably extensive microthrombi in the absence of depleted coagulation factors.

Clinically “DIC” and endotheliopathy-associated DIT/VMTD (i.e., TTP-like syndrome) are exactly the same in their underlying risk factors and presentation. Both almost always occur in critical illnesses (e.g. sepsis/septic shock, trauma, immunologic and collagen-vascular diseases, and complications of surgery, pregnancy and transplant) [32,33]. Pathologically both are characterized by arteriolar and capillary hyaline microthrombic with variable fibroblastic proliferation [34,35]. Hematologically they also present with TCIP and MAHA/aMAHA. Thus, “DIC” and DIT are exactly the same disorder.

Microthrombogenesis and activated TF coagulation pathway

According to the “two-activation theory of the endothelium” DIT induced by microthrombogenesis is completely different from true DIC occurring as a result of activated TF coagulation pathway. Their characteristic difference is shown in Table 2. The former is pathological microthrombotic disorder, but the latter is abnormal hemostatic (coagulation) disorder. Considering the difference in their pathogenic mechanisms, “DIC” must have been understood with a wrong pathogenesis. Hence, “DIC” is a misnomer. More than 60 years, this unfortunate misconception of “DIC” has created confusion in medical science and practice, including diagnostic dilemma and treatment failures until today.

  Endotheliopathy-associated DIT/VMTD True DIC
Examples TTP-like syndrome (endotheliopathy-associated) APL
Nature of the disorder Microthrombosis made of platelet-ULVWF complexes Coagulation activated by TF-FVIIa complexes
Mechanism of the genesis Intravascular microthrombogenesis Intravascular coagulation
Inciting events Sepsis; trauma; complications of surgery, pregnancy and transplant; and drugs/toxins leading to endotheliopathy Acute promyelocytic leukemia and drugs (?) leading to TF expression
Hematological manifestations TTP-like syndrome Hemorrhagic disease of APL
Mechanism Activation of microthrombotic pathway/microthrombogenesis Activation of TF-FVIIa pathway
Site of activation Endothelium Intravascular space
Pathology Endothelial activation/dysfunction® endotheliopathy TF expression ® coagulation and factor depletion
Result of pathogenesis Formation of platelet-ULVWF microthrombi Consumption of fibrinogen, FVIII, FV
Essence of pathology Arteriolar and capillary lumenal microthrombi Incoagulable blood/unstable blood clots
Effect on the involved organs Vascular microthrombosis leading to organ hypoxia Hemorrhage leading to organ damage
Coagulation tests
Fibrinogen; Normal Decreased
PT; aPTT; TT; Normal Prolonged
FDP Normal Increased
FVIII activity Normal or increased Markedly decreased
Thrombocytopenia Moderately severe Mild to very severe
Associated clinical syndromes TTP-like syndrome Hemorrhagic disorder
Associate hematologic features
Schistocytes 0 - +++ 0 - + (?)
MAHA/aMAHA Often present Absent
Consumptive thrombocytopenia Always present Present (?)
Incidence in clinical practice Very common Extremely rare
Platelet transfusion Contraindicated May be needed in leukemia
Treatment TPE; rADAMTS13 (expected to be very effective) Treat underlying pathology (e.g., ATRA in APL)

Table 2: Hematological and clinical characteristics of endotheliopathy-associated DIT/VMTD and true DIC; APL: Acute Promyelocytic Leukemia; aPTT: Activated Partial Thromboplastin Time; aMAHA/MAHA: Atypical Microangiopathic Hemolytic Anemia/ Microangiopathic Hemolytic Anemia; ATRA: All-Trans Retinoic Acid; DIC: Disseminated Intravascular Coagulation; DIT: Disseminated Intravascular Thrombosis; FV: Factor V; FVIIa: Activated Factor VII; FVIII: Factor VIII; FDP: Fibrin Degradation Products; TMA: Microthrombotic Angiopathy; PT: Prothrombin Time; TF: Tissue Factor; TPE: Therapeutic Plasma Exchange; TT: Thrombin Time; MODS: Multi-Organ Dysfunction Syndrome; rADAMTS13: Recombinant ADAMTS13; SIRS: Systemic Inflammatory Response Syndrome; TTP: Thrombotic Thrombocytopenic Purpura; VMTD: Vascular Microthrombotic Disease.

If one understands and accepts the fact that “DIC” is a misnomer but its euonym is endotheliopathy-associated DIT, Ebola haemorrhagic fever can be explained perfectly well by the concept of DIT. The next question is how Ebola haemorrhagic fever gets haemorrhagic disorder. Another word, “What is the correct diagnosis for “DIC” that is associated with abnormal coagulation profile?” In Ebola, acute fulminating hepatitis/acute hepatic necrosis, especially multifocal necrosis type, occurs without a good explanation [5,36-40]. With “two-activation theory” this can be easily explained by endotheliopathyassociated DIT/VMTD causing hepatic microthrombosis and acute hepatic necrosis syndrome, leading to hepatic coagulopathy [5]. Indeed, hepatic coagulopathy shows exactly the same coagulation profile as seen in “acute DIC”.

True DIC is very rare but occurs perhaps in acute promyelocytic leukemia, presumably due to TF expression from leukemic cells [41]. As illustrated in Table 2, the predominant feature of true DIC is a haemorrhagic disorder without MAHA/ aMAHA or hypoxic organ dysfunction [30,41,42]. In differentiating true DIC from hepatic coagulopathy, the most important test is the assay of coagulation factors, especially FVIII and FV, which are depleted in DIC. More importantly, in hepatic coagulopathy, FVIII is normal or increased although it is markedly decreased in DIC [5,42-44]. Also, a markedly decreased liver dependent FVII occurs in hepatic coagulopathy. A suggested guideline for laboratory tests is presented in Table 3 to aid the differential diagnosis among complicated thrombopathies and coagulopathies [5].

  TTP and TTP-like syndrome (DIT) TTP-like syndrome (DIT) associated with HC (e.g. Ebola)=acute “DIC” DIC (e.g. acute promyelocytic leukemia) PF (e.g., amyloidosis)
Thrombocytopenia Always present Always present Always present Not present
MAHA/aMAHA Almost always present Usually present Very unlikely to be present Not present
Fibrinogen Normal Decreased Always decreased Always decreased
Factor VIII Normal Normal or increased Markedly decreased Decreased
Factor V Normal Decreased Decreased Decreased
Factor X Normal Decreased Usually normal Normal
Factor VII Normal Markedly decreased Normal Normal
Factor IX Normal Decreased Normal Normal
FDP Normal Positive Positive Strongly positive
Thrombin time Normal Prolonged Prolonged Prolonged
Thrombosis form Microthrombi Microthrombi Friable macrothrombi (?) or not formed Absent
Bleeding: Character Rare, mild petechiae May cause serious bleeding Common, serious bleeding Slow & persistent bleeding
Treatment Usually no need of treatment Controllable with FFP Abrogated with ATRA & chemotherapy Treatable with AFA
Platelet transfusion Contraindicated Contraindicated May be used with ATRA Not needed

Table 3: Differential characteristic hematologic features among thrombopathies and coagulopathies (Adapted and modified from Chang [5] with permission); TTP: Thrombotic Thrombocytopenic Purpura; HC: Hepatic Coagulopathy; DIT: Disseminated Intravascular Thrombosis; DIC: Disseminated Intravascular Coagulation; PF: Primary Fibrinolysis; FDP: Fibrin Degradation Products; MAHA: Microangiopathic Hemolytic Anemia; aMAHA: Atypical MAHA; FFP: Fresh Frozen Plasma; AFA: Anti-Fibrinolytic Agents; ATRA: All- Trans Retinoic Acid.

In Ebola haemorrhagic fever, TCIP is the earliest indicator suggesting that microthrombogenesis is in progress. If a haemorrhagic disorder occurs, it is neither due to DIC nor due to thrombocytopenia alone, but most likely is due to hepatic coagulopathy occurring with endotheliopathy-associated DIT/ VMTD. In Ebola haemorrhagic fever, the “two activation theory” not only explains the concomitant inflammation, TCIP and progressive hypoxic organ dysfunction, but also would help to unmask unrecognized syndromes such as coming cytokine “storm”, TTP-like syndrome, MAHA/aMAHA, MODS and SIRS as illustrated in Figure 1.


Ebola haemorrhagic fever is due to endotheliopathyassociated DIT/VMTD, which hematologic manifestation is TTPlike syndrome. If the diagnosis is confirmed, in addition to the best supportive care, the treatment for Ebola haemorrhagic fever should include fresh frozen plasma for hepatic coagulopathy and therapeutic plasma exchange for TTP-like syndrome.


Select your language of interest to view the total content in your interested language

Viewing options

Post your comment

Share This Article

Flyer image
journal indexing image

Post your comment

captcha   Reload  Can't read the image? click here to refresh